One step forward, one step sideways? Expanding research capacity for neglected diseases.

BMC International Health and Human Rights
Joel Lexchin

Abstract

There is general agreement, including from the pharmaceutical industry, that current market based methods of generating research into the development of pharmaceutical products that are relevant for developing countries do not work. This conclusion is relevant not just for the most neglected diseases such as leishmaniasis but even for global diseases such as cancer and cardiovascular disease. Stimulating research will mean overcoming barriers such as patent thickets, poor coordination of research activities, exclusive licensing of new technologies by universities and the structural problems that inhibit conducting appropriate clinical trials in developing countries. In addition, it is necessary to ensure that the priorities for research reflect the needs of developing countries and not just donors. This article will explore each of these issues and then look at three emerging approaches to stimulating research -paying for innovation, priority review sales or vouchers and public-private partnerships, - and evaluate their strengths and weaknesses. All of the stakeholders agree that there is a pressing need for a major expansion in the level of R&D. Whatever that new model turns out to be, it will have to deal with the 5 barriers ...Continue Reading

References

Jun 6, 1992·BMJ : British Medical Journal·P C WallerM D Rawlins
May 23, 1998·Science·M A Heller, R S Eisenberg
Feb 12, 2004·Journal of Medical Ethics·A A HyderL Dawson
May 16, 2006·Lancet·Pierre Chirac, Els Torreele
May 20, 2006·Bulletin of the World Health Organization·Tomris Türmen, Charles Clift
Sep 21, 2006·Health Policy and Planning·Jeremy Shiffman
Oct 24, 2006·Social Science & Medicine·Kent Buse, Andrew M Harmer
Dec 23, 2006·BMJ : British Medical Journal·Joseph E Stiglitz
Oct 9, 2007·Contemporary Clinical Trials·Sergio Sismondo
May 24, 2008·Science·T J Tucker, M W Makgoba
Nov 7, 2008·The New England Journal of Medicine·Aaron S Kesselheim
Nov 15, 2008·American Journal of Public Health·Bhaven N Sampat
Apr 23, 2009·BMJ : British Medical Journal·Elizabeth Sukkar
Aug 26, 2009·Bulletin of the World Health Organization·Jeremy Shiffman
Nov 26, 2009·Archives of Internal Medicine·Steven Woloshin, Lisa M Schwartz

❮ Previous
Next ❯

Citations

Mar 1, 2013·Open Biology·Elizabeth BilslandStephen G Oliver
Oct 13, 2011·PLoS Neglected Tropical Diseases·Elizabeth BilslandStephen G Oliver
Nov 22, 2011·Future Medicinal Chemistry·Graeme M Robertson, Lorenz M Mayr
Aug 24, 2011·Future Medicinal Chemistry·Stephanie A Robertson, Adam R Renslo
Mar 4, 2014·Global Public Health·Catherine Olivier, Bryn Williams-Jones
Jan 11, 2012·The American Journal of Tropical Medicine and Hygiene·Laura W MusselwhiteEthan Guillen

❮ Previous
Next ❯

Software Mentioned

HIF

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.